Liraglutide offered superior glycemic control to sitagliptin in patients with type 2 diabetes who had inadequate glycemic control on metformin, according to a recent report in The Lancet.
Liraglutide offered superior glycemic control to sitagliptin in patients with type 2 diabetes who had inadequate glycemic control on metformin, according to a recent report in The Lancet.
A 26-week, randomized, parallel-group, open-label trial enrolled patients aged 18 to 80 years with type 2 diabetes mellitus who had inadequate glycemic control (glycosylated hemoglobin [HbA1c] 7.5% to 10.0%) on metformin (>1,500 mg daily for >3 months). Treatment with subcutaneous liraglutide administered once daily at either 1.2 mg (n=225) or 1.8 mg (n=221) per dose lowered HbA1c to a greater extent than 100 mg of oral sitagliptin administered once daily (n=219) [–0.60% (95% CI, –0.77 to –0.43; P.0001) for 1.8 mg and –0.34% (95% CI, –0.51 to –0.16; P.0001) for 1.2-mg liraglutide dose compared to sitagliptin]. Consequently, a greater proportion of patients receiving liraglutide achieved the HbA1c goal of
Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, supplies biologic activity similar to native GLP-1, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 and GIP, which are rapidly released after meals, increase glucose-dependent insulin secretion. Furthermore, GLP-1, also suppresses glucagon secretion, delays gastric emptying, and decreases appetite. Currently two GLP-1 analogs, liraglutide and exenatide, and two DPP-4 inhibitors, sitagliptin and saxagliptin, are approved for marketing by FDA.
The researchers note in their paper, “In accordance with the consensus algorithm for the treatment of type 2 diabetes mellitus by the American Diabetes Association and the European Association for the Study of Diabetes, our results support the use of liraglutide to achieve glycemic goals in patients with inadequate control on metformin.”
The current “consensus algorithm” or guidelines published in 2009 by the major American and European diabetes medical organizations recommend that selection of drug therapy for treatment of type 2 diabetes be based on a drug’s ability to reduce hyperglycemia (in particular, HbA1c). Guidelines recommend that patients inadequately treated with metformin monotherapy (and lifestyle modification) should be initiated on either sulfonylureas or insulin. Pioglitazone and the GLP-1 analogs may also be selected and are listed as tier 2 drugs. However, DPP-4 inhibitors (as well as other common antidiabetic agents) get only cursory mention due to the consensus panel’s assessment that there is limited data supporting their efficacy.
In addition to its superiority on glucose lowering, this new trial suggests that liraglutide significantly reduces body weight to a greater extent than sitagliptin [–2.42 kg (95% CI, –3.14 to –1.70) for 1.8-mg liraglutide versus sitagliptin, and –1.90 kg (95% CI, –2.61 to –1.18) for 1.2- mg liraglutide versus sitagliptin]. Minor hypoglycemia was recorded in about 5% of patients in each treatment group.
The complete findings of this randomized controlled trial were published in the April 24, 2010, edition of The Lancet along with a detailed on-line appendix.
SOURCES
Pratley RE, Nauck M, Bailey T, et al; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–1456.
Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.